Shares of AngioDynamics Inc. (NASDAQ:ANGO) saw unusually-strong trading volume on Friday . Approximately 132,680 shares traded hands during trading, a decline of 3% from the previous session’s volume of 137,293 shares.The stock last traded at $14.50 and had previously closed at $14.39.

Several equities analysts recently issued reports on ANGO shares. Canaccord Genuity cut AngioDynamics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $14.50 to $13.00 in a research note on Tuesday, April 5th. Piper Jaffray Cos. assumed coverage on AngioDynamics in a research report on Friday, April 8th. They issued a “neutral” rating and a $12.00 target price on the stock. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Friday, May 20th. Finally, KeyCorp dropped their target price on AngioDynamics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, April 8th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $14.10.

The company has a 50-day moving average of $13.21 and a 200 day moving average of $11.91. The firm’s market cap is $525.25 million.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, April 7th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. During the same period last year, the firm posted $0.12 earnings per share. The business earned $87.40 million during the quarter. The company’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts anticipate that AngioDynamics Inc. will post $0.56 earnings per share for the current year.

In other news, SVP Stephen A. Trowbridge sold 12,940 shares of the company’s stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $12.30, for a total transaction of $159,162.00. Following the completion of the transaction, the senior vice president now directly owns 32,469 shares of the company’s stock, valued at $399,368.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Charles R. Greiner sold 3,508 shares of the company’s stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $12.31, for a total value of $43,183.48. Following the transaction, the vice president now directly owns 20,910 shares of the company’s stock, valued at $257,402.10. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors boosted its position in AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock valued at $1,073,000 after buying an additional 63,332 shares in the last quarter. Morgan Stanley boosted its position in shares of AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock valued at $1,198,000 after buying an additional 5,728 shares during the period. Whitebox Advisors LLC bought a new position in shares of AngioDynamics during the fourth quarter valued at approximately $1,384,000. Principal Financial Group Inc. boosted its position in shares of AngioDynamics by 5.2% in the fourth quarter. Principal Financial Group Inc. now owns 174,319 shares of the company’s stock valued at $2,116,000 after buying an additional 8,640 shares during the period. Finally, Royce & Associates LLC boosted its position in shares of AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock valued at $7,779,000 after buying an additional 102,098 shares during the period.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.